The purpose of this study was to examine the motivational, attitudinal, and behavioral predictors of interest in genetic testing (GT) in those with and without awareness of their risk for type 2 diabetes (T2DM).
Methods
A convenience sample of adults visiting emergency departments, libraries, or an online research registry was surveyed. Responses from adults without diabetes who reported 1 or more risk factors for T2DM (eg, family history, body mass index > 25) were included in the analyses (n = 265).
Results
Participants were 37 ± 11 years old, white (54%), and female (69%), with some college education (53%) and an annual income below $25 000 (44%). Approximately half (52%) expressed interest in GT for T2DM. Individuals were stratified by perceived risk for T2DM (risk aware or risk unaware). Among the risk aware, younger age (P < .04) predicted greater interest in GT. Among the risk unaware, family history of T2DM (P < .008) and preference to know genetic risk (P < .0002) predicted interest in GT. Both groups identified the need for low-cost GT.
Conclusions
GT is an increasingly available and accurate tool to predict T2DM risk for patients. In this sample, GT was a salient tool for those with and without awareness of their T2DM risk. Financial accessibility is critical to use of this tool for both groups.
American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36:1033-1046.
3.
KnowlerWCBarrett-ConnorEFowlerSE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
4.
ScottRALagouVWelchRP. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44:991-1005.
5.
MorrisAPVoightBFTeslovichTM. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:981-990.
6.
VoightBFScottLJSteinthorsdottirV. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579-589.
7.
ZegginiEScottLJSaxenaR. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008;40:638-645.
8.
SaxenaRVoightBFLyssenkoV. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331-1336.
9.
ScottLJMohlkeKLBonnycastleLL. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341-1345.
10.
ZegginiEWeedonMNLindgrenCM. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336-1341.
11.
SladekRRocheleauGRungJ. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445:881-885.
12.
GloynALWeedonMNOwenKR. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52:568-572.
13.
AltshulerDHirschhornJNKlannemarkM. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.
14.
GrantSFThorleifssonGReynisdottirI. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-323.
15.
HelgasonAPalssonSThorleifssonG. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet. 2007;39:218-225.
16.
ReynisdottirIThorleifssonGBenediktssonR. Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2. Am J Hum Genet. 2003;73:323-335.
17.
Bouatia-NajiNRocheleauGVan LommelL. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science. 2008;320:1085-1088.
DupuisJLangenbergCProkopenkoI. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105-116.
20.
ManningAKHivertMFScottRA. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012;44:659-69.
21.
Bouatia-NajiNBonnefondACavalcanti-ProencaC. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89-94.
22.
LyssenkoVJonssonAAlmgrenP. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220-2232.
23.
VassyJLDasmahapatraPMeigsJB. Genotype prediction of adult type 2 diabetes from adolescence in a multiracial population. Pediatrics. 2012;130:e1235-e1242.
24.
VassyJLDurantNHKabagambeEK. A genotype risk score predicts type 2 diabetes from young adulthood: the CARDIA study. Diabetologia. 2012;55:2604-2612.
25.
de Miguel-YanesJMShraderPPencinaMJ. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care. 2011;34:121-125.
26.
van HoekMDehghanAWittemanJC. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes. 2008;57:3122-3128.
27.
TalmudPJHingoraniADCooperJA. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ. 2010;340:b4838.
28.
VaxillaireMVeslotJDinaC. Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes. 2008;57:244-254.
29.
MeigsJBShraderPSullivanLM. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208-2219.
30.
PearsonH. Genetic testing for everyone. Nature. 2008;453:570-571.
31.
KatsanisSHJavittGHudsonK. Public health: a case study of personalized medicine. Science. 2008;320:53-54.
BonettaL. Getting up close and personal with your genome. Cell. 2008;133:753-756.
34.
BelskyDWMoffittTEHoutsR. Polygenic risk, rapid childhood growth, and the development of obesity: evidence from a 4-decade longitudinal study. Arch Pediatr Adolesc Med. 2012;166:515-521.
35.
MacArthurDGLekM. The uncertain road towards genomic medicine. Trends Genet. 2012;28:303-305.
36.
KedesLLiuET. The Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet. 2010;42:917-918.
37.
KedesLLiuEJongeneelCVSuttonG. Judging the Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet. 2011;43:175.
38.
KedesLCampanyG. The new date, new format, new goals and new sponsor of the Archon Genomics X PRIZE competition. Nat Genet. 2011;43:1055-1058.
39.
BrunhamLRHaydenMR. Medicine: whole-genome sequencing. The new standard of care?Science. 2012;336:1112-1113.
40.
GreeleySAJohnPMWinnAN. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care. 2011;34:622-627.
41.
GrantRHivertMPandiscioJFlorezJNathanDMeigsJ. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia. 2009;52:2299-2305.
42.
ScheunerMTSieverdingPShekellePG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA. 2008;299:1320-1334.
43.
GrantRWO’BrienKEWaxlerJL. Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care. 2013;36:13-19.
44.
WaxlerJLO’BrienKEDelahantyLM. Genetic counseling as a tool for type 2 diabetes prevention: a genetic counseling framework for common polygenetic disorders. J Genet Couns. 2012;21:684-691.
45.
De VellisRF. Scale Development: Theory and Applications. 3rd ed.Los Angeles, CA: Sage; 2012.
